Drs Sparks and Neuen discuss the proper use of SGLT2 inhibitors to prevent chronic kidney disease, including how to start them and monitor them and their possible side effects.
Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/971884). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.
Resources
SGLT2 Inhibitors in Primary Care: 'All Hands on Deck' for Improving Heart Failure Outcomes https://www.medscape.com/viewarticle/965473
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/nejmoa1611925
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy https://www.nejm.org/doi/full/10.1056/nejmoa1811744
CKD Epidemiology Collaboration CKD-EPI Consortium https://www.tuftsmedicalcenter.org/research-clinical-trials/institutes-centers-labs/chronic-kidney-disease-epidemiology-collaboration/overview
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes https://www.nejm.org/doi/full/10.1056/NEJMoa2025845
Net Effects of Sodium-Glucose Co-Transporter-2 Inhibition in Different Patient Groups: A Meta-Analysis of Large Placebo-Controlled Randomized Trials https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00443-0/fulltext
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin) https://www.empakidney.org/
FDA Removes Boxed Warning About Risk of Leg and Foot Amputations for the Diabetes Medicine Canagliflozin (Invokana, Invokamet, Invokamet XR) https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-removes-boxed-warning-about-risk-leg-and-foot-amputations-diabetes-medicine-canagliflozin